VAKCINA

Additionally, U.S. NIH COVID-19 Treatment Guidelines updated to recommend use of sotrovimab , to treat nonhospitalized patients with mild to moderate COVID-19 who are at high risk of clinical progression, as defined by the Emergency Use Authorization (EUA)https://t.co/b5hZ1zPXUN

— Antibiotic Steward Bassam Ghanem (@ABsteward) June 21, 2021

An EU deal with health care company @GSK will buy up to 220,000 treatments of Sotrovimab, a monoclonal antibody therapy for #COVID patients with mild symptoms.https://t.co/yW89XWOazf

— EURACTIV (@EURACTIV) July 29, 2021

Health Minister ⁦@GregHuntMP⁩ announced the federal government purchased 7700 doses of Sotrovimab, a monoclonal antibody treatment, on the weekend https://t.co/d9g0LAyb2Q

— James Massola (@jamesmassola) August 12, 2021

As far as supply is concerned, the companies currently have about 450,000 sotrovimab doses on hand, Vir’s Scangos said. The companies are also revving up their manufacturing network to crank out roughly 2 million doses for the first year of emergency supply in the U.S. The antibody itself is made by WuXi and Samsung Biologics in China and South Korea, respectively, before it’s finished and distributed from GSK’s facility in Parma, Italy, Scangos said.

Samsung is currently coming online with high-volume manufacturing, and the companies “think in the following year, we can make many more than two million doses available,” he added.

To develop its drug, Vir “deliberately isolated an antibody that binds to a part of the virus that is very difficult for the virus to mutate,” he said. That piece of the virus is “conserved, not only in all the variants, but in SARS-1 … and in a whole family of coronaviruses.”

Orders for sotrovimab are up 300% from last month, a company spokesperson said.

Meanwhile, Regeneron is seeing a big windfall from its successful pandemic treatment. The company reported $2.59 billion in antibody sales in the second quarter, which was more than the $2.53 billion figure the entire company generated in the first quarter. 
The U.S. pays $2,100 per dose for the treatment, White House advisor Marcella Nunez-Smith told Bloomberg. More than 600,000 doses have been administered in the U.S.
Antibodies are provided free to Americans considered at high risk of developing severe disease. And the pool of those considered such has grown. In May, the FDA expanded its criteria, lowering the threshold for unhealthy weight and including race and ethnicity as factors. University of North Carolina Health infectious disease expert David Wohl told The Wall Street Journal that the pool of eligible people now includes 75% of American adults. 

Koga zanima - 3.doza fajzera posle 2 sinofarma ( mama 49 godište, hronicne bolesti prisutne). pic.twitter.com/EPx2TZ7WYB

— Danijela (@1976generacija) September 7, 2021

Nije pre 3.doze ali je radila posle 2.doze. Na testu gde je ref.vr 1 imala je 3.71.

— Danijela (@1976generacija) September 7, 2021

2 nedelje. Tako savetuju pre provere.

— Danijela (@1976generacija) September 7, 2021

Erős Pista wrote:

Majka 1, otac 0.2, supruga 0.2. Granična vrednost 1. Ja ću videti za par dana, mesec dana posle vakcine sam imao preko 100.

— Марко Лазаревић (@BluezNinja) September 7, 2021

Bad news on #MuVariant—Japanese scientists: "Mu variant is highly resistant to sera from convalescent & [Pfizer]-vaccinated people. Direct comparison of different spike proteins revealed that Mu spike is more resistant…than all other current variants”https://t.co/Ilf5gh3OGd pic.twitter.com/DbdJVGZTjz

— Eric Feigl-Ding (@DrEricDing) September 8, 2021

ontheotherhand wrote:Muuuuu

Bad news on #MuVariant—Japanese scientists: "Mu variant is highly resistant to sera from convalescent & [Pfizer]-vaccinated people. Direct comparison of different spike proteins revealed that Mu spike is more resistant…than all other current variants”https://t.co/Ilf5gh3OGd pic.twitter.com/DbdJVGZTjz

— Eric Feigl-Ding (@DrEricDing) September 8, 2021

“All sera efficiently neutralized the SARS-CoV-2 B.1.621 isolate demonstrating that this VOI is not a concern for vaccine efficacy." This is around a 2-fold reduction. You can find the study here: https://t.co/811X3iNg41 H/T: @gutoaqui

— Chise 🧬🧫🦠 (@sailorrooscout) September 8, 2021

That’s the issue here. I guarantee you he doesn’t realize that study uses pseudovirus (which produces varying results ALL the time) over this one that utilized live. Live > Pseudo always.

— Chise 🧬🧫🦠 (@sailorrooscout) September 8, 2021

You’re probably right, which burns me up even more honestly.

— Chise 🧬🧫🦠 (@sailorrooscout) September 8, 2021

Spoiler:

Srbija dobija fabriku za Sinofarm vakcine – kapacitet 40 miliona doza godišnje 

Predsednik Srbije Aleksandar Vučić izjavio je da veruje da će projekat za izgradnju fabrike za proizvodnju vakcina kineske kompanije Sinofarm biti ostvaren u interesu građana Srbije i celog regiona. Reč je o zajedničkom ulaganju Srbije, Кine i Ujedinjenih Arapskih Emirata u vrednosti 30 miliona evra.
Vučić je prilikom ceremonije postavljanja kamena temeljca u Zemunu naveo da će u toj fabrici, pored proizvodnje, „biti sposobni da se usavršavaju i da pune nove komponente za buduće vakcine“.
Istakao je da je kapacitet fabrike 40 miliona doza godišnje, a da je „naš plan“ da se proizvede 30 miliona, „što je dovoljno za Srbiju, region i sve koji su zainteresovani“.
„Bićemo među prvima u svetu koji će imati mogućnost da zajedno sa partenerima iz Kine i UAE menjamo sadržaj supstance i da budemo među prvima u svetu koje će blagodeti naučnih otkrića moći da podelimo sa narodom i da efikasnot i kvalitet vakcina bude na još višem nivou“, kazao je Vučić.
Naglasio je da je kineska vakciona „apsolutno sigurna i da ima široko polje dejstva“.
„Ponosan sam što će Srbija u saradnji sa Kinom i UAE imati fabriku koja će vakcinama snabdetvati i zemlje regiona i Evrope i što nismo čekali da nam neko drugi ponudi rešenje u borbi protiv pandemije već mi uspevamo da rešavamo deo regionalnih i globalnih problema“, kazao je Vučić.
On je naveo da će do kraja marta iduće godine biti zavaršen prvi pogon gde će se puniti kineske vakcione, do kada će se punjenje Sinofarm vakcine raditi u Hemofarmu. U drugoj fazi, do 2023. godine, biće izgrađen i pogon gde će se proizvoditi aktivna supstanca za vakcionu.
„U fabrici će u prvoj fazi raditi 180 ljudi, od kojih će 40 odsto biti visokosteučni kadrovi, a u drugoj fazi će biti zaposleno još 100 radnika“, rekao je Vučić.
Svečanosti povodom polaganja kamena temeljca za fabriku vakciona prisustvovali su i ministar zdravlja Zlatibor Lončar, ambasadorka Kine u Srbiji Čen Bo, gradonačelnik Beograda Zoran Radojičić, generalni i izvršni direktor kompanije Mubadals iz UAE Kaldun Al Mubarak i generalni direktor kineske kompanije Grupa 42 Peng Sijao.